Of note, Hew et al. (2016) have described that MAPK activation predicts poor outcome in ER-positive high grade ovarian cancer and showed that MEK inhibition reversed anti-oestrogen resistance in an appropriate model system. This evidence concerns the gene MAP2K7 and ovarian cancer.